Liang J, Tian XF, Yang W. Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137. World J Gastroenterol 2020; 26(13): 1474-1489 [PMID: 32308348 DOI: 10.3748/wjg.v26.i13.1474]
Corresponding Author of This Article
Wei Yang, MD, Chief Physician, Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Avenue, Changchun 130000, Jilin Province, China. 18345893430@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 7, 2020; 26(13): 1474-1489 Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1474
Effects of long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on colon cancer cell resistance to oxaliplatin and its regulation of microRNA-137
Jing Liang, Xiao-Feng Tian, Wei Yang
Jing Liang, Department of Gastrointestinal Surgery, China-Japan Union Hospital of Jilin University, Changchun 130000, Jilin Province, China
Xiao-Feng Tian, Wei Yang, Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130000, Jilin Province, China
Author contributions: Yang W performed the majority of experiments and analyzed the data; Liang J performed the molecular investigations; Tian XF and Yang W designed and coordinated the research, and wrote the paper.
Institutional review board statement: This study was reviewed and approved by the China-Japan Union Hospital of Jilin University Ethics Committee.
Informed consent statement: All patients in our study provided informed consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei Yang, MD, Chief Physician, Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Avenue, Changchun 130000, Jilin Province, China. 18345893430@163.com
Received: December 4, 2019 Peer-review started: December 4, 2019 First decision: January 16, 2020 Revised: February 4, 2020 Accepted: March 9, 2020 Article in press: March 9, 2020 Published online: April 7, 2020 Processing time: 125 Days and 3.9 Hours
ARTICLE HIGHLIGHTS
Research background
Recently, colon cancer (CC) has displayed a high incidence, and the main treatment of CC is chemotherapy. Oxaliplatin (L-OHP) is a common drug used in chemotherapy, but long-term use can result in drug resistance, seriously affecting the prognosis of patients.
Research motivation
Long non-coding RNA Opa-interacting protein 5 antisense RNA 1 (OIP5-AS1) appears to be up-regulated, which plays a tumor-promoting role in a number of cancers. It is speculated that miR-137 may be effective in mediating drug resistance in CC cells.
Research objectives
To determine the effect of long non-coding RNA OIP5-AS1 on drug resistance in CC cell lines and its role in regulating miR-137.
Research methods
We not only analyzed the expression levels of OIP5-AS1 and miR-137 in surgical CC tissue samples, but also observed their effects on the biological behavior of CC cells as well as L-OHP resistance.
Research results
We noted high expression of OIP5-AS in CC tissues and cells and low expression of miR-137. In cytological studies, it was found that reducing OIP5-AS1 expression or increasing miR-137 expression controlled the proliferation, invasion and migration of CC cells, promoting the apoptosis rate of tumor cells by regulating the expression of apoptosis-related proteins.
Research conclusions
OIP5-AS1 is highly expressed in CC, which contributes to regulation of the biological behavior of CC cells as well as drug resistance to L-OHP in CC cells via mediation of miR-137 expression.
Research perspectives
This study reveals the mechanism of OIP5-AS1 in drug resistance to L-OHP in CC cells, which provides a new method to improve the sensitivity of CC cells to L-OHP.
